Howard Marks
Oaktree Capital Management
Howard Marks ASSERTIO THERAPEUTICS INC stake
total: 853
Oaktree Capital Management ASRT-OLD2 trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2019 Q3
- Held for:
- 3 quarters
- Latest activity:
- 2020 Q2
According to 2026 Q2 report, Howard Marks doesn't hold any ASSERTIO THERAPEUTICS INC (ASRT-OLD2) shares. To date, the estimated cost basis is nearly $1.28 for "buy" trades and estimated average "sell" price is $0.65. Oaktree Capital Management first purchased ASRT-OLD2 in 2019 Q3, initially acquiring about 1.49M shares. Since the initial investment in ASSERTIO THERAPEUTICS INC (ASRT-OLD2), Oaktree Capital Management has made 1 more transaction.
When did Howard Marks sell ASSERTIO THERAPEUTICS INC (ASRT-OLD2)?
Howard Marks sold off the entire ASSERTIO THERAPEUTICS INC (ASRT-OLD2) position in 2020 Q2.
When did Howard Marks buy ASSERTIO THERAPEUTICS INC (ASRT-OLD2)?
Howard Marks first invested in ASSERTIO THERAPEUTICS INC (ASRT-OLD2) in 2019 Q3 at the reported quarter-end price of $1.28 per share.
What's the cost basis of Oaktree Capital Management's ASRT-OLD2 stake?
The estimated cost basis for ASSERTIO THERAPEUTICS INC (ASRT-OLD2) stake is around $1.28 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $1.28
- Weighted AVG sell price:
- $0.65
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.